Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

737
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
737
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

733
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
733

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.

Haematologica·2021
Same author

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

British journal of haematology·2021
Same author

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.

Blood cancer journal·2021
Same author

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet. Oncology·2021
Same author

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.

Blood·2021
Same author

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine·2021

Related Experiment Video

Updated: Dec 25, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

363

Bortezomib.

Hermann Einsele1

  • 1Department of Internal Medicine II, University Hospital Würzburg, Josef-Schneider Straße 2, 97080, Wurzburg, Germany, Einsele_h@klinik.uni-wuerzburg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|April 24, 2014
PubMed
Summary
This summary is machine-generated.

Proteasome inhibitors, targeting protein degradation, are crucial for cellular processes and cancer therapy. Bortezomib, a key inhibitor, has significantly improved multiple myeloma treatment.

More Related Videos

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
09:18

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

5.0K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

363
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
09:18

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

5.0K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The ubiquitin-proteasome system regulates critical cellular functions including protein turnover, cell cycle, apoptosis, and immune responses.
  • Dysregulation of this system presents therapeutic opportunities, particularly in cancer treatment.
  • Proteasome inhibitors were initially developed as research tools to study proteasome activity.

Purpose of the Study:

  • To review the development and therapeutic applications of proteasome inhibitors.
  • To highlight the significance of the ubiquitin-proteasome system as a drug target.
  • To discuss the clinical impact of approved proteasome inhibitors.

Main Methods:

  • Review of scientific literature on proteasome inhibitors and their mechanisms.
  • Analysis of clinical trial data and therapeutic outcomes for proteasome inhibitor drugs.
  • Synthesis and characterization of peptide-based and natural product inhibitors.

Main Results:

  • Proteasome inhibitors, including bortezomib (boronic acid) and carfilzomib (epoxy ketone), effectively target proteasome activity.
  • Natural products like lactacystin and salinosporamide A also exhibit proteasome inhibitory effects.
  • Bortezomib demonstrated efficacy in various cancers, including multiple myeloma, non-small-cell lung, and prostate cancer.

Conclusions:

  • Proteasome inhibitors have emerged as significant therapeutic agents, particularly in hematological malignancies.
  • Bortezomib's approval has revolutionized multiple myeloma treatment, improving patient outcomes.
  • The ubiquitin-proteasome system remains a promising target for novel drug development in oncology.